'Bionanotechnology from Theory to Practice' is a short online, course providing an interdisciplinary and up-to-date overview of the rapidly developing area of bionanotechnology
Page URL: https://www.bionews.org.uk/page_134621

23andMe test for cancer risk gains FDA approval

12 March 2018
Appeared in BioNews 941

The first direct-to-consumer test for cancer risk genes has been approved by the US Food and Drug Administration (FDA).

Personal genetics company 23andMe received approval for a genetic test for three of the roughly 1000 mutations in the BRCA1 and BRCA2 genes that are associated with an increased risk of developing breast, ovarian and prostate cancer. While these mutations are common in people of Ashkenazi Jewish descent, with one in 40 individuals carrying them, they are rare in the wider population.

The new test 'has a lot of caveats', said Donald St. Pierre, at the FDA's Centre for Devices and Radiological Health. 'While the detection of a BRCA mutation on this test does indicate an increased risk, only a small percentage of Americans carry one of these three mutations and most BRCA mutations that increase an individual's risk are not detected by this test.'

Women with the genetic variants assessed by 23andMe's test have a 45-85 percent higher chance of developing breast cancer by the age of 70. 'This authorisation is incredibly valuable for those who might not be aware of their Ashkenazi Jewish descent or aren't familiar with their family history of cancer,' said Anne Wojcicki, CEO and co-founder of 23andMe.

But Wojcicki, along with the FDA and other experts cautioned that a negative report from 23andMe on these three BRCA mutations does not exclude the possibility of a person carrying another BRCA mutation associated with an increased risk of developing cancer. 'For other groups with different […] mutations, and there are many, it won't help much. There's a big need for users to understand that nuance, which is not widely understood,' Dr Robert Cook-Deegan at Arizona State University, told STAT.

23andMe's test relies on a saliva sample to test for the BRCA mutations. Normally, only women with a family history of breast cancer get referred for genetic testing to investigate their BRCA status. If mutations which increase the risk of developing cancer are found, preventive measures include regular check-ups, potential lifestyle changes and possibly preventive surgery.

5 August 2019 - by Francesca Sowerbutts 
23andMe advertises itself on its website as a way to 'meet your genes'. You can send off a spit sample, and for $99-$199, a report based on your genetics will be emailed to you a few weeks later...
22 July 2019 - by Shaoni Bhattacharya 
Geneticists in the UK have been speaking out against direct-to-consumer DNA testing after concerns over false positive results...
28 January 2019 - by Martha Henriques 
The US Food and Drug Administration has approved a direct-to-consumer genetic test for a hereditary form of colorectal cancer by 23andMe...
5 November 2018 - by Kulraj Singh Bhangra 
The US Food and Drug Administration has approved the first consumer pharmacogenetic test, but not without crucial caveats...
30 July 2018 - by Dr Alexander Ware 
The pharmaceutical firm GlaxoSmithKline is investing US$300 million in 23andMe as part of a four-year collaboration that will give it access to the DNA testing firm's genetic data resources...
26 February 2018 - by Debbie Kennett 
2017 was the year that personal genetic testing took off in a big way...
12 February 2018 - by Ruth Retassie 
Nebula Genomics, a new firm founded by geneticists, has announced its plan to sequence customers’ genomes cheaply and allow them to sell their own genomic information for digital money...
5 February 2018 - by Shaoni Bhattacharya 
A large study of the genomes of over 1.3 million people has found 956 genes implicated in insomnia...
31 October 2016 - by Kulraj Singh Bhangra 
Personal genomics company 23andMe has halted plans to develop next-generation sequencing technology, it has revealed ...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.